The most common recommendations for targeted therapies are PARP inhibitors and immune checkpoint inhibitors, based on PGVs in homologous directed repairs, especially BRCA1 and BRCA2, and Lynch syndrome-associated genes, respectively [60, 31, 12]. The gene discussed is BRCA1; the disease is Lynch syndrome.